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located more than 92 nucleotides up-
stream to the 30-most exon–exon junc-
tion (Mu¨ller et al., 2006). K10 transcript
levels in the normal skin of the hetero-
zygous father were B50% compared
with the wild type (Figure 2b). Hetero-
zygous family members are clinically
unaffected, which indicates that one
K10 allele is sufficient to maintain a
normal phenotype.
In the previously reported homozy-
gous EH patients (Mu¨ller et al., 2006)
and in the present proband, K6, K16, and
K17 are upregulated in the absence of
human K10 protein and show a maximal
expression at the sites of cytolysis (data
not shown). In addition, suprabasal
persistence of the basal keratin, K14,
was found in our patient and in the
recessive EH patient reported by Tsubota
et al. (2008). In the K10 knockout
mouse, decreased proteolysis and supra-
basal persistence of the basal keratins,
K5, K14, and K15, were shown, and
keratin aggregates were found to consist
of residual K1 that formed atypical
heterodimers with K14 (Reichelt et al.,
2001). Formation of instable atypical
heterodimers between residual K1 and
another type I keratin, for example, K16
or K17, which form relatively poor
intermediate filaments compared with
those built up from keratins constitutively
expressed in the epidermis (Takahashi
et al., 1994; Paladini et al., 1996), could
additionally contribute to skin fragility
and cytolysis in recessive EH.
In conclusion, the characteristic
ultrastructural picture consisting of
sparse keratin filaments and keratin
clumps that show a nearly homogenous,
amorphous structure should prompt a
detailed analysis of the pedigree to
search for parental consanguinity and a
recessive inheritance. All reported muta-
tions in recessive EH to date are located
in close proximity in the 2B domain of
K10 (Figure 2c), suggesting a genetic
hotspot in recessive EH. Expanding
the catalog of known mutations in this
disorder is important with respect
to molecular diagnosis and genetic
counseling.
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TO THE EDITOR
Most symptoms of allergic disease are
caused by mast cell (MC) activation and
subsequent release of mediators, parti-
cularly histamine (Metz and Maurer,
2007; Metz et al., 2008). Research
shows that preformed histamine is stored
in large amounts in cutaneous MC
granules (Metz and Maurer, 2007).
Currently, the most common way to
treat MC-driven diseases, such as allergicAbbreviations: Ca, calcium; MC, mast cell
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rhinitis or urticaria, is by administering
H1-antihistamines (Młynek et al., 2008).
Agents that inhibit activation of MCs and
release of inflammatory mediators, such
as histamine, that is, MC stabilizers, may
provide additional benefits in these
conditions (Wang et al., 2005).
For the skin, agents for long-term
treatment with specific MC-stabilizing
properties remain to be elucidated. Of
interest are recent reports, suggesting
that some of the anti-allergic effects of
non-sedating second-generation anti-
histamines, such as desloratadine, may
be a result of MC-stabilizing properties
(Zhao et al., 2004; Kowalski et al.,
2005; Wang et al., 2005). Desloratadine
has been shown to inhibit histaminic,
allergic, and inflammatory responses in
murine and in vitro studies (Baena-
Cagnani, 2001). However, because the
inhibitory effects of desloratadine on
human skin MC activation and mediator
release have not been studied in detail,
convincing data on a possible MC-
stabilizing effect on allergic MC activa-
tion are scarce (Genovese et al., 1997),
and information on its effects on non-
allergic activation of normal human MCs
is lacking. Therefore, a study was con-
ducted to explore whether desloratadine
inhibits activation of human skin MCs
and subsequent mediator release,
whether such properties (if present) are
dose dependent, and whether inhibition
is limited to specific stimulators.
Mast cells were obtained by human
skin collection during cosmetic surgery
for which donors provided written
informed consent. This study was con-
ducted according to the Declaration of
Helsinki and approved by the Institu-
tional Review Board of the Charite´–
Universita¨tsmedizin Berlin in Germany.
Purification of cells was achieved by
incubation with CD117 magnetic beads
and subsequent separation of labeled
from unlabeled cells by passing them
over the AutoMACS System (Miltenyi
Biotech, Bergisch Gladbach, Germany).
The isolated and purified human skin
MCs were preincubated for 60 minutes
with 200ml of vehicle (PIPES albumin
glucose with calcium and magnesium;
Sigma-Aldrich, Munich, Germany) or
desloratadine in concentrations of
1108 to 1104 M. All MCs were
subsequently stimulated for 30 minutes
with 400 ml of desloratadine or vehicle
containing (final concentrations) anti-
IgE (0.67 mg ml1), calcium (Ca)-iono-
phore (0.2 mM), or substance P (30 mM),
after which expression of CD107a was
detected and histamine release was
quantified. An earlier study has con-
firmed that CD107a, also known as
lysosome-associated membrane protein
1, is a previously unknown marker of
MC activation and degranulation
(Gru¨tzkau et al., 2004). On flow cyto-
metry of normal, resting human skin
MCs, CD107a is only expressed at low
levels on the cell surface. After stimula-
tion with anti-IgE, Ca-ionophore, or
substance P, intracellular CD107a is
rapidly translocated to the cell mem-
brane, and its expression can be well
detected by fluorescent-activated cell
sorter analysis employing anti-CD107a
antibodies.
The statistical analysis for this study
was based on a two-tailed Student’s
t-test for unpaired samples. The results
of this analysis showed that deslorata-
dine significantly inhibited CD107a
expression on human skin MCs after
stimulation with each of the three test
substances (Figure 1). At the highest
desloratadine concentration, the inhibi-
tory effect was strongest in response to
stimulation with anti-IgE (50.7% inhibi-
tion; Po0.05), followed by substance P
(48.0% inhibition; Po0.005), and Ca-
ionophore (26.7% inhibition; Po0.01).
The absolute number of CD107a-posi-
tive cells in percentage of total cells
after stimulation (set as 100%) were
50.1%, 61.3, and 59.8% for anti-IgE,
substance P, and Ca-ionophore, respec-
tively. The inhibitory action of deslorat-
adine was dose dependent with all
three test substances.
Desloratadine also significantly in-
hibited histamine release by human
skin MCs after stimulation with each
of the three test substances (Figure 2).
At the highest desloratadine concentra-
tion, the inhibitory effect was strongest
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Figure 1. Effect of desloratadine (DL) on CD107a expression on human skin mast cells after stimulation with anti-IgE, substance P, or calcium (Ca)-ionophore.
CD107a expression after stimulation of pretreated cells with each individual test substance is calculated as a percentage (mean±SE) of release without
desloratadine pretreatment (set to 100%). The results are pooled from three or four independent experiments.
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in response to stimulation with sub-
stance P (53.7% inhibition; Po0.01),
followed by anti-IgE (42.6% inhibition;
Po0.005), and Ca-ionophore (39.9%
inhibition; Po0.005). Substance P-
induced histamine release was also
significantly inhibited at desloratadine
concentrations of 106 M and 108 M
(9.8 and 13.0% inhibition, respectively;
Po0.005 for both). The absolute hist-
amine release in percentage of the total
cell histamine content after stimulation
(set as 100%) was 21.8, 49.2, and
60.9% for anti-IgE, substance P, and
Ca-ionophore, respectively.
No cytotoxicity was observed with
desloratadine incubation of MCs at any
of the drug concentrations (data not
shown).
On the basis of these findings, we
conclude that preincubation with de-
sloratadine significantly inhibits expres-
sion of the MC-activation marker,
CD107a, as well as subsequent hist-
amine release, in primary human
skin MCs. Moreover, the effects of
desloratadine are not limited to IgE-
dependent stimulation, but also extend
to IgE-independent pathways, such as
Ca-ionophore and substance P. Deslor-
atadine can therefore be considered as
an effective MC stabilizer in vitro. We
also determined that this effect is
generally dose dependent, with higher
doses of desloratadine showing more
potent inhibitory effects. One possible
mechanism, by which desloratadine
might exert its inhibitory effect on
MCs is an interference either with
intracellular calcium accumulation or
with activation of intracellular calcium-
dependent enzymes, for example, cal-
modulin.
Our results are in line with the
earlier reports showing that the release
of tumor necrosis factor by phorbol
myristate acetate- or Ca-ionophore-
stimulated human leukemic MCs is
inhibited in a dose-dependent fashion
by the antihistamines, azelastine, cetir-
izine, or loratadine, at concentrations
that the authors concluded could be
easily achieved therapeutically in the
tissue (Lippert et al., 2000). Although
little data are available on skin con-
centrations of desloratadine at recom-
mended dosing levels, one study found
that skin concentrations 24 hours after a
single 5-mg oral dose of desloratadine
approached those that achieved signifi-
cant MC stabilization in this study
(Frossard et al., 2008). Further investiga-
tion is warranted to clarify the cellular
pathways involved in desloratadine-in-
duced inhibition of CD107a expression
and histamine release, and to assess the
clinical effects of this inhibition on MC-
mediated diseases of the skin.
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Figure 2. Effect of desloratadine (DL) on histamine release by human skin mast cells after stimulation with anti-IgE, substance P, or calcium (Ca)-ionophore.
Histamine release after stimulation of pretreated cells with each individual test substance is calculated as a percentage (mean±SE) of release without
desloratadine pretreatment (set to 100%). The results are pooled from three or four independent experiments.
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TO THE EDITOR
Leprosy, caused by Mycobacterium
leprae, presents a spectrum of findings,
with tuberculoid leprosy at one end
and lepromatous leprosy at the other.
Although humoral immune responses
are observed throughout the spectrum,
cell-mediated immunity is observed in
the tuberculoid leprosy form of the
disease (Ridley and Jopling, 1966). We
previously showed a much stronger
association of the HLA allele, DRB1*
1501, with multibacillary leprosy than
with tuberculoid leprosy and a signifi-
cant decrease of DRB1*0701 in multi-
bacillary leprosy as compared with the
tuberculoid form and controls (Rani
et al., 1993). This suggested that HLA
alleles may play a role in differentiating
the manifestations of leprosy. However,
an integrated role for genes involved in
immune responses cannot be ruled out.
Given that the T cells are anergic to
M. leprae antigens in leprosy patients,
we explored the role of protein tyrosine
phosphatase non-receptor type 22
(PTPN22) in that disease.
PTPN22 encodes for an 807 amino
acid residue protein called LYP (lym-
phoid tyrosine phosphatase), which
has been shown to negatively regulate
T-cell signaling (Hasegawa et al.,
2004). A single-nucleotide polymorph-
ism in the PTPN22 gene at nucleotide
position 1858 C4T (codon 620), resul-
ting in an arginine-to-tryptophan (CGG
to TGG) transition, has been shown
to be a gain-of-function mutation, with
a more potent negative regulation of
T-cell signaling through reduced Lck
(leukocyte-specific protein tyrosine
kinase)-mediated phosphorylation of
the TCRx chain, reduced tyrosine phos-
phorylation of LAT (linker for activation
of T cells), and reduced activation of
Erk2 (Vang et al., 2005). The mutant,
LYP-Trp620, has been associated
with several autoimmune diseases
(Begovich et al., 2004; Bottini et al.,
2004; Kyogoku et al., 2004) Recently,
Chapman et al. (2006) have shown its
involvement in invasive pneumococcal
disease and Gram-positive bacterial
disease. Owing to its involvement in
the downregulation of T-cell function
and in invasive bacterial disease, one
could hypothesize that LYP-Trp620 has
a role in the manifestation of mycobac-
terial diseases as well.
To study the role of the PTPN22
C1858T single-nucleotide polymor-
phism, 153 leprosy patients from
North India—103 lepromatous patients,
including borderline lepromatous
patients (79 men and 24 women
with a mean (±SD) age of 32.26±
11.84 years), and 50 tuberculoid
patients, including borderline tubercu-
loid patients (38 men and 12 women
with a mean (±SD) age of 31.35±9.16
years)—diagnosed on the basis of
immunological, histopathological, and
bacteriological status, were compared
with 365 ethnically matched healthy
controls (191 men and 174 women
with a mean (±SD) age of 36.02±
10.31 years), using PCR followed by
restriction digestion with the enzyme
Rsa1, as described by Zheng and She
(2005). The study was approved by the
Human Ethics Committees of Ram
Manohar Lohia Hospital and National
Institute of Immunology. The restriction
endonuclease, Rsa1, cleaves the DNA
strand that contains the C nucleotide at
the 1858th position and exhibits two
bands of 176 and 42 bp. The mutant,
1858T, however, is not digested by
Rsa1 and shows a single band of 218 bp
(Supplementary Figure 1). All samples
showing CT heterozygosity were re-
peated for both amplification and re-
striction digestion by another individual
to confirm the genotyping. A total of
20% of the CC homozygous samples
were repeated for both amplification
and restriction digestion randomly, and
the restriction digestion clearly showed
the 176 bp band.
The frequency of the 1858T allele
was significantly higher in both lepro-
matous (Po0.00006) and tuberculoid
(Po0.001) leprosy patients than in
normal healthy controls (Table 1).
Although homozygous 1858TT was
absent from both groups of patients,
as well as from the control samples
studied, heterozygous CT was signifi-
cantly increased in both groups of
patients (Table 1). All genotype
frequencies in patients as well as in
controls were in Hardy–Weinberg equi-
librium. The allele frequency of theAbbreviations: PTPN22, protein tyrosine phosphatase non-receptor type 22
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